Approval claim
Compounded does not mean approved
As of September 26, 2026, claiming FDA approval for a compounded medicine is false; compounded preparations do not have that approval.
What to avoid / check the loose ends
Pause where an answer is missing.
Look at the product, the prescription process and the support after the visit. A polished page cannot answer those checks for you.
Words used in this note
- NDC
- National Drug Code, a number identifying a medicine on FDA’s drug list. That list names products reported to FDA; it is not a list of approved medicines.
- Adverse event
- A problem that happens while someone uses a medicine. That alone does not prove the medicine caused it.
- MedWatch
- A reporting program for medical product problems.
Question a claim that skips the product review
Food and Drug Administration (FDA) reviews a proposed medicine’s evidence in the US.
Drug code
A drug number is not FDA approval
As of September 26, 2026, FDA says an NDC number used to identify a medicine does not prove FDA approval.
- Ask for the exact product record.
- Ask for the reason compounding is proposed.
- Keep broad claims of being “the same” as a question to resolve.
Check that a health review leads to the prescription
A form can collect your medical history. Before deciding on care, the health professional must understand the health problem and be able to ask follow-up questions.
As of September 26, 2026, federal prescription rules forbid supplying prescription medicine without a valid prescription.
State medical boards get guidance from a group named the Federation of State Medical Boards. It advises against choosing treatment solely from an unchanging online form that cannot collect all the details needed.
The group’s advice about forms is a suggested professional standard, not itself an Alabama law. Alabama’s own rules govern care in the state.
- Ask who reviews your history and can ask more questions.
- Ask how to reach a clinician after the medicine arrives.
- Resolve an unnamed pharmacy before agreeing to the plan.
Clear instructions matter with compounded injections
Discuss unclear instructions with the prescriber and pharmacist rather than working them out from a web page.
GLP-1, a body hormone, plays a part in hunger and blood-sugar control. Some medicines act like it.
As of September 26, 2026, FDA had received reports that people measured incorrect amounts of injectable compounded semaglutide. Some needed hospital care.
GLP-1 shots include semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) injections. As of September 17, 2026, FDA’s advice is to avoid GLP-1 injections that arrive warm or with too little cooling.
That advice concerns those injectable products; storage requirements are not identical across all peptide medicines.
- Ask the pharmacy to explain the product label.
- Ask for the written storage and delivery plan.
- Keep the package and care documents when raising a concern.
Know where a concern belongs
A product report and a professional complaint follow different paths.
FDA’s free MedWatch program lets you report medicine problems straight to the agency.
MedlinePlus provides public health information and describes severe allergic reactions as emergencies that can threaten life.
For severe symptoms such as difficulty breathing or tongue swelling, its guidance is to seek emergency care.
Keep going
Take useful questions to the visit